美国国家乳腺摄影数据库中筛查乳腺摄影召回后BI-RADS 3类的癌症检出率及随访模式
该回顾性研究纳入2009年1月至2018年3月471家国家乳腺摄影数据库机构中筛查召回后评估为BI-RADS 3类的45202名女性,分析6、12、24个月随访的癌症检出率和活检阳性预测值。2年累积癌症检出率为1.86%(95%CI 1.73%, 1.98%),活检率11.2%,PPV3为16.6%,810例恶性肿瘤中468例(57.8%)在6个月或之前诊断,验证了短期随访的必要性。
要点
- BI-RADS 3类病变2年累积癌症检出率1.86%(95%CI 1.73%, 1.98%),支持其作为可能良性类别使用。
- 6个月随访时活检率9.5%(3001/31465),癌症检出率1.5%(456/31465;95%CI 1.3%, 1.6%)。
- 810例恶性肿瘤中468例(57.8%)在6个月或之前诊断,支持短期随访的必要性。
核心结论
- 在国家乳腺摄影数据库中,BI-RADS 3类的使用是适当的,2年随访累积癌症检出率为1.86%。
- 810例恶性肿瘤中468例(57.8%)在6个月或之前诊断,验证了对乳腺摄影BI-RADS 3类病变进行短期随访的必要性。
研究设计与样本
- 回顾性研究,纳入2009年1月至2018年3月471家国家乳腺摄影数据库机构中筛查乳腺摄影召回后额外评估为BI-RADS 3类的女性。
- 仅分析年龄25岁及以上、无个人乳腺癌史女性的首次BI-RADS 3类发生,随访方式为活检或2年影像随访,共45202名女性(中位年龄55岁,范围25-90岁)。
诊断标准与关键数值
- BI-RADS 3类病变在检测时活检者1574例(3.5%),检出72例癌症,癌症检出率4.6%(72/1574)。
- 6个月随访时31465名女性中3001例(9.5%)活检,456例(15.2%)恶性,癌症检出率1.5%(456/31465;95%CI 1.3%, 1.6%)。
- 12个月随访时18748名女性中1219例(6.5%)活检,230例(18.9%)恶性,癌症检出率1.2%(230/18748;95%CI 1.1%, 1.4%)。
- 2年随访时活检率11.2%(4894/43628),癌症检出率1.86%(810/43628;95%CI 1.73%, 1.98%),PPV3为16.6%(810/4894)。
临床应用与阅片要点
- BI-RADS 3类病变在筛查召回后额外评估中首次发现时,可参照短期间隔随访模式进行管理。
- 6个月随访中多数恶性肿瘤(57.8%)在6个月或之前诊断,阅片和报告中应重视短期随访的落实。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The literature supports the use of short-interval follow-up as an alternative to biopsy for lesions assessed as probably benign, Breast Imaging Reporting and Data System (BI-RADS) category 3, with an expected malignancy rate of less than 2%. Purpose To assess outcomes from 6-, 12-, and 24-month follow-up of probably benign findings first identified at recall from screening mammography in the National Mammography Database (NMD). Materials and Methods This retrospective study included women recalled from screening mammography with BI-RADS category 3 assessment at additional evaluation from January 2009 through March 2018 from 471 NMD facilities. Only the first BI-RADS category 3 occurrence for women aged 25 years or older with no personal history of breast cancer was analyzed, with biopsy or 2-year imaging follow-up. Cancer yield and positive predictive value of biopsies performed (PPV3) were determined at each follow-up. Results Among 45 202 women (median age, 55 years; range, 25-90 years) with a BI-RADS category 3 lesion, 1574 (3.5%) underwent biopsy at the time of lesion detection, yielding 72 cancers (cancer yield, 4.6%; 72 of 1574 women). For the remaining 43 628 women who accepted surveillance, 922 were seen within 90 days (with 78 lesions biopsied and 12 [15%] classified as malignant). The women still in surveillance (31 465 of 43 381 women [72.5%]) underwent follow-up mammography at 6 months. Of 3001 (9.5%) lesions biopsied, 456 (15.2%) were malignant (cancer yield, 1.5%; 456 of 31 465 women; 95% confidence interval [CI]: 1.3%, 1.6%). Among 18 748 of 25 997 women (72.1%) in surveillance who underwent follow-up at 12 months, 1219 (6.5%) underwent biopsy with 230 (18.9%) malignant lesions found (cancer yield, 1.2%; 230 of 18 748 women; 95% CI: 1.1%, 1.4%). Through 2-year follow-up, the biopsy rate was 11.2% (4894 of 43 628 women) with a cancer yield of 1.86% (810 malignancies found among 43 628 women; 95% CI: 1.73%, 1.98%) and a PPV3 of 16.6% (810 malignancies found among 4894 women). Conclusion In the National Mammography Database, Breast Imaging Reporting and Data System (BI-RADS) category 3 use is appropriate, with 1.86% cumulative cancer yield through 2-year follow-up. Of 810 malignancies, 468 (57.8%) were diagnosed at or before 6 months, validating necessity of short-interval follow-up of mammographic BI-RADS category 3 findings. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Moy in this issue.
引用
- Berg WA, Berg JM, Sickles EA, et al. Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database. Radiology. 2020. PMID: 32427557. doi:10.1148/radiol.2020192641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。